Every material Form 8-K Jazz Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Jazz Pharmaceuticals reported third-quarter 2025 total revenue of $1.13 billion, up 7% from a year earlier, and GAAP net income of $251.4 million, or $4.08 per diluted share, compared with $215.1 million, or $3.42 per share, in the prior-year quarter. The company raised its 2025 non-GAAP adjusted net income guidance to $475 million to $525 million from $300 million to $350 million, but nine-month GAAP results show a net loss of $559.6 million due to a large acquired in-process R&D charge and litigation settlements.
Q3 2025 total revenues were $1,126.1 million, up from $1,055.0 million in Q3 2024.
GAAP net income was $251.4 million ($4.08 per diluted share) versus $215.1 million ($3.42) a year earlier.
2025 non-GAAP adjusted net income guidance rose to $475 million-$525 million from $300 million-$350 million.
Nine-month GAAP net loss was $559.6 million, compared with net income of $369.0 million in the prior-year period.
Jazz Pharmaceuticals said its board appointed Dr. Ted Love as a director effective December 1, 2025, and he will join the Audit and Science and Medicine committees. Director Kenneth W. O'Keefe will retire from the board on the same date, and the filing says his decision was not due to any dispute with the company. The change is a routine board update that does not include financial results or guidance.
Dr. Ted Love appointed to the board effective December 1, 2025, as a Class I director with a term expiring at the 2027 annual meeting
Dr. Love joins the Audit Committee and Science and Medicine Committee
Kenneth W. O'Keefe will retire from the board effective December 1, 2025; the filing says no dispute or disagreement led to his decision
Board decision on Love appointment dated October 23, 2025; filing dated October 28, 2025
Jazz reported second-quarter 2025 total revenues of $1.05 billion, up 2% from a year earlier, but posted a GAAP net loss of $718.5 million after a $905.4 million acquired in-process R&D charge tied to the Chimerix acquisition. The company lowered the top end of its full-year 2025 revenue guidance to $4.15 billion to $4.30 billion and named Renee Gala President and CEO effective August 11, 2025.
Q2 2025 total revenues were $1.05 billion, up from $1.02 billion in Q2 2024.
GAAP net loss was $718.5 million, or $11.74 per diluted share, versus GAAP net income of $168.6 million, or $2.49 per share, in Q2 2024.
The net loss includes a $905.4 million acquired IPR&D charge for dordaviprone, which reduced results by $14.78 per share on a GAAP basis.
2025 total revenue guidance is now $4.15 billion to $4.30 billion, down from $4.15 billion to $4.40 billion at the top end; GAAP net loss guidance is $(565) million to $(450) million.
Jazz Pharmaceuticals said its board appointed President and Chief Operating Officer Renee Gala as President and Chief Executive Officer, effective August 11, 2025, and she will join the board as a director on that date. Co-founder Bruce Cozadd will serve as CEO until August 11, 2025, then in a transition role through September 12, 2025, before retiring and remaining Chairperson of the Board.
Gala becomes CEO and a director effective August 11, 2025; the board increases from 12 to 13 members.
Gala's annual base salary rises to $1,200,000 from $900,000, and her target bonus to 110% of base salary from 80%.
A one-time promotion equity grant with an approximate grant date value of $6,500,000 is included, on top of her previous 2025 annual grant of approximately $6,000,000.
Cozadd remains in a transition role through September 12, 2025, then retires and continues as Chairperson.
Jazz reported first-quarter 2025 total revenues of $897.8 million, roughly flat with $902.0 million a year earlier, and a GAAP net loss of $92.5 million, or $1.52 per share, versus a $14.6 million loss in the prior-year quarter. The loss reflects a $172.0 million expense for Xyrem antitrust litigation settlements, and the company cut its 2025 profit guidance while affirming its revenue range of $4.15 billion to $4.40 billion.
Q1 2025 non-GAAP adjusted net income was $105.2 million, or $1.68 per diluted share, down from $178.4 million, or $2.63, in Q1 2024.
2025 GAAP net loss guidance is now $(615) million to $(450) million, versus prior net income guidance of $560 million to $720 million.
2025 non-GAAP adjusted net income guidance is now $250 million to $350 million, versus prior guidance of $1.4 billion to $1.5 billion.
The guidance change reflects the April 2025 Chimerix acquisition, which the company completed for approximately $935 million in cash.
Jazz Pharmaceuticals Ireland Limited agreed on April 7, 2025 to a preliminary class settlement with indirect Xyrem purchasers, paying $145 million in a lump sum from cash on hand. The company expects a pre-tax charge of about $145 million in the first quarter of 2025, and the deal remains subject to court approval. Shareholders face a known cash cost and a charge, and the company warns that further settlements with other plaintiffs may add significant charges.
Lump-sum payment of $145 million, funded with cash on hand
Expected pre-tax charge of approximately $145 million in the first quarter of 2025
Settlement requires Court approval and can be rescinded if a specified percentage of potential class members opt out
Company may enter additional settlements with remaining plaintiffs, which could be significant; the company denies wrongdoing
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Jazz Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →